Gain Therapeutics, Inc. (NASDAQ:GANX) Receives $8.50 Average PT from Analysts

Gain Therapeutics, Inc. (NASDAQ:GANX) has received a consensus recommendation of “Moderate Buy” from the five brokerages that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $8.50.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Gain Therapeutics in a report on Friday, April 10th.

Institutional Investors Weigh In On Gain Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Millennium Management LLC bought a new stake in Gain Therapeutics during the 4th quarter valued at about $45,000. Engineers Gate Manager LP bought a new stake in Gain Therapeutics during the 4th quarter valued at about $47,000. OMERS ADMINISTRATION Corp bought a new stake in shares of Gain Therapeutics in the 4th quarter valued at about $120,000. Marshall Wace LLP raised its holdings in shares of Gain Therapeutics by 849.3% in the 4th quarter. Marshall Wace LLP now owns 1,662,293 shares of the company’s stock valued at $5,353,000 after purchasing an additional 1,487,186 shares in the last quarter. Finally, State Street Corp raised its holdings in shares of Gain Therapeutics by 72.9% in the 4th quarter. State Street Corp now owns 157,537 shares of the company’s stock valued at $507,000 after purchasing an additional 66,400 shares in the last quarter. Institutional investors own 11.97% of the company’s stock.

Gain Therapeutics Trading Up 3.9%

Shares of GANX opened at $2.13 on Friday. Gain Therapeutics has a 1-year low of $1.41 and a 1-year high of $4.34. The company has a 50-day moving average of $2.14 and a 200 day moving average of $2.39. The firm has a market capitalization of $89.97 million, a price-to-earnings ratio of -3.49 and a beta of 0.11. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.63 and a quick ratio of 6.63.

Gain Therapeutics (NASDAQ:GANX) last announced its quarterly earnings data on Thursday, March 26th. The company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.03. On average, research analysts expect that Gain Therapeutics will post -1 EPS for the current year.

About Gain Therapeutics

Gain Therapeutics, Inc (NASDAQ: GANX) is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain’s lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.